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Type 2 diabetes mellitus (T2DM) has recently been recognized as a significant risk
factor for bone fragility. Careful investigations of bone mechanical properties in human
studies suggested possible alterations of bone composition, although this axis has
poorly been investigated. The main aim of this study was to evaluate the impact
of high fat diet-induced diabetes and therapy using the clinically approved GLP-1
receptor agonist, exenatide, on tissue bone mechanical properties and compositional
parameters. Male mice had free access to high fat diet for 16 weeks to induce
diabetes prior to commencement of the study. Exenatide was administered twice
daily by i.p. injection at a dose of 25 nmol/kg for 52 days. Normal and high fat
diet fed (HFD) mice injected with saline were used as controls. Bone mechanical
properties was assessed at the organ level by 3-point bending and at the tissue
level by nanoindentation. Bone microarchitecture was investigated by microcomputed
tomography and bone composition was evaluated by Fourier transform infrared imaging.
HFD mice exhibited profound alterations of bone mechanical properties at both the
organ and tissue level. Collagen maturity as well as trabecular and cortical bone
microarchitectures were abnormal. Administration of exenatide, led to clear ameliorations
in bone mechanical properties at the organ and tissue levels by modifications of both
cortical microarchitecture and bone compositional parameters (collagen maturity, mineral
crystallinity, carbonate/phosphate ratio, acid phosphate content). These results bring
new light on the mode of action of exenatide in bone physiology and demonstrate the
value of GLP-1 mimetics in the treatment of fragility fractures in diabetes.
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INTRODUCTION
Diabetes mellitus is now considered an independent risk factor for bone fragility fractures (1, 2).
Patients with type 2 diabetes mellitus (T2DM) present with normal or slightly elevated values
for bone mineral density, even when normalized for body mass index (3, 4). Paradoxically,
T2DM is associated with an augmentation in the frequency of fragility fractures (5–7).
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The possible explanation for this elevated fracture occurrence
may reside in T2DM-related complications (reduced muscle
quality, retinopathy, nephropathy, poor balance and increased
falls), abnormal glycemic control and anti-diabetic medications
that may compromise bone quality (8), i.e., an ensemble of
structural and compositional properties that are very important
for bonemechanical properties (9). Indeed, an elegant study from
Farr and colleagues using the OsteoProbe R© microindentation
device reported lower bone material mechanical properties index
in post-menopausal T2DM patients as compared with controls
(10). Taken together, these observations suggest alterations of
bone in T2DM at the compositional levels. Compositional
parameters, regrouping specific properties of the bone mineral
and collagen, have already been correlated with mechanical
strength and fracture risk (11) in osteoporosis but have scarcely
been investigated in T2DM and even less so in response to
anti-diabetic medications.
Glucagon-like peptide 1 (GLP-1) is a hormone produced
by enteroendocrine L-cells, located primarily in the ileum and
colon (12). GLP-1 is an incretin hormone that potentiates
glucose-mediated insulin secretion by pancreatic beta cells.
Previous studies have suggested that patients with T2DM
have an attenuated response to endogenous GLP-1 and that
infusion of exogenous synthetic GLP-1 could be considered a
treatment option (13). As such, several GLP-1 mimetics have
been developed and approved for the treatment of T2DM and
randomized clinical trials demonstrated the superiority of GLP-
1 receptor agonists to other antidiabetic drugs in reducing
HbA1c and blood pressure, and initiating weight loss without
hypoglycemia risk (14). Despite a relative high cost, GLP-1
receptor agonists are increasingly been prescribed to T2DM
patients. Among all GLP-1 receptor agonists, exenatide was the
first molecule approved for the treatment of T2DM in 2005.
Exenatide is a synthetic derivative of exendin-4, a naturally
occurring peptide found in salivary secretion of the Gila monster
lizard, with a 53% amino acid sequence overlap with humanGLP-
1 (15). Exenatide has a longer duration of action and similar
receptor binding and cAMP release properties than endogenous
GLP-1 (16).
Meta-analysis of randomized clinical trials or observational
studies, although supporting a beneficial role of GLP-1
receptor agonists in reducing HbA1c levels, reported divergent
conclusions on the beneficial actions of GLP-1 analogs in
reducing fracture risk (17–20). However, these studies presented
several limitations that may hamper skeletal interpretation. In
rodent models, the use of GLP-1 receptor agonists augmented
bone mass and ameliorated bone structural properties in
ovariectomy-induced bone loss (21–24) or genetically inherited
T2DM models (25–27). However, despite the fact that GLP-
1 receptor deficient animals present with alterations of bone
composition (28), little is known about the action of GLP-1
receptor agonists on bone compositional parameters in T2DM,
although changes in collagen and mineral properties have been
suspected to play a role in the etiology of fragility fractures
in T2DM.
Therefore, the aims of the present study were (i) to evaluate
whether the high-fat diet (HFD) diabetic mouse model presents
with alterations of bone composition and (ii) to ascertain whether
the use of a GLP-1 receptor agonist, exenatide, improves skeletal
health in this model.
MATERIALS AND METHODS
Reagents
Exenatide (Ex) was purchased from GL Biochem Ltd. (Shangai,
China). Purity and molecular mass were verified by high
performance liquid chromatography and matrix-assisted laser
desorption/ionization-time of flight mass spectrometry. All other
chemicals were obtained from Sigma-Aldrich (Lyon, France)
unless otherwise stated.
Animals
Male NIH Swiss mice (Hsd:NIHS) were obtained from Envigo
Ltd (Blackthorn, UK) at 8 weeks of age. Animals were
individually housed in an air-conditioned room at 22 ± 2◦C
with a 12-h light/dark cycle, and were provided with tap water
and high fat diet (45% fat, 20% protein, 35% carbohydrate for
a total of 26.2 kJ/g; Special Diet Service, Essex, UK) ad libitum.
In an unpublished pilot study, we observed that after 112 days
on high fat diet, mice exhibited significantly increased body
weight and hyperglycaemia (fasting glucose level >14 mmol/l)
as well as a 40% reduction in trabecular bone mass and a 27%
reduction in cortical thickness at the femur. High fat diet diabetic
(HFD) mice were then divided into two matched groups (n =
8) that received twice daily saline (0.9% NaCl – HFD + saline)
or exenatide (25 nmol/kg bw – HFD + Ex) intraperitoneally for
52 days. This protocol was chosen based on positive metabolic
and bone-associated effects observed using related peptide-based
drugs with similar dosing regimens and animal models (29,
30). Normal male mice (n = 8), fed a standard rodent diet
(10% fat, 30% protein and 60% carbohydrate for a total of 13
kJ/g; Trouw Nutrition, Northwich, UK) and injected twice daily
with saline were used as controls (Lean + saline). Figure 1
represents a schematic of the experimental design. All procedures
were conducted according to UK Home Office Regulations (UK
Animals Scientific Procedures Act 1986) and approved by the
Ulster University Institutional animal care committee. At the
end of the study, body weight, average daily food intake, non-
fasting plasma glucose and insulin levels, glucose tolerance test
and insulin sensitivity were assessed as reported previously (31).
Bone mineral density (BMD, g/cm2) and total body fat (g) were
measured with a Lunar PIXImus scanner (Inside Outside Sales,
Wisconsin, U.S.A.) as described previously (30). At necropsy,
femurs and tibias were cleaned of soft tissues and stored in 70%
ethanol until used, as described below.
MicroCT
MicroCT analyses were performed with a Skyscan 1172
microtomograph (Bruker MicroCT, Kontich, Belgium) operated
at 70 kV, 100 µA, 340-ms integration time. The isotropic pixel
size was fixed at 4µm, the rotation step at 0.25◦ and exposure
was done with a 0.5-mm aluminum filter. To calibrate for bone
mineral density, hydroxyapatite (HA) rods (2-mm diameter, at
hydroxyapatite densities of 0.25 and 0.75 gHA/cm3) and volumes
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FIGURE 1 | Schematic representation of the experimental design used in this study.
of saline and air were also scanned with the same parameters.
Each 3D reconstruction image dataset was binarized using global
thresholding. Trabecular volume of interest (VOI) was located at
the proximal tibia, 0.5mm below the growth plate and extended
2mm down. Using the hydroxyapatite calibration scans, the
grayscale dataset was transformed into Hounsfield units (HU)
by assigning an HU value of 0 to the average grayscale index of
saline, and an HU value of −1,000 to black pixels (air). Next,
average HU values for the two mineralized phantoms (0.25 and
0.75 gHA/cm3) were used to create a linear relationship between
HU and mineral density.The threshold value to discriminate
mineralized tissue from bone marrow was set at 0.4 g/cm3 and
resulting binarized images were compared visually with original
images. All microCT parameters were determined according to
guidelines and nomenclature proposed by the American Society
for Bone and Mineral Research (32).
Bone Histomorphometry
After microCT, tibias were embedded, undecalcified in
methylmethacrylate at 4◦C to preserve enzyme activities.
Sagittal sections (7-µm thickness) were performed on a heavy
duty microtome equipped with a 50◦ tungsten carbide knife.
Four non-serial sections were stained with toluidine blue for
the measurement of bone marrow adiposity and the number
of osteoblasts. Four additional sections were stained for the
osteoclastic tartrate resistant acid phosphatase (TRAcP). Four
sections were stained with Goldner Trichrome. Regions of
interest were located 0.5mm below the growth plate and
extended 3mm down. Standard bone histomorphometrical
nomenclatures, symbol and units were used as described in
the report of the American Society for Bone and Mineral
Research (33).
Bone Mechanical Properties Assessment
Three-point bending experiments were performed on femurs
after rehydrating bones at 4◦C for 24 h. This test investigates
the overall resistance of the whole bone that depends from both
the structural and the compositional properties and represents
the strength at the organ level. Measurements were done
with an Instron 5942 (Instron, Elancourt, France) as reported
previously (34). Briefly, the span length was fixed at 10mm
and femurs were positioned horizontally with the anterior face
downward. The press head was applied vertically to the midshaft
with a loading speed of 2 mm/min until failure. The load-
displacement curve was acquired with the Bluehill 3 software
(Instron). Ultimate load, ultimate displacement, stiffness and
total absorbed energy were computerized (35). After three-
point bending experiments, distal portions of femur were
embedded undecalcified in polymethylmethacrylate at 4◦C and
cross-sections were made at the midshaft using a diamond
saw (Accutom, Struers, Champigny sur Marne, France). Cross-
sections were polished to a 1-µm finish with diamond particles
(Struers, France) and subjected to rehydration in saline 24 h
prior to nanoindentation testing. Nanoindentation testing is
independent of the overall bone microstructure and hence
represents the strength of the bone matrix at the tissue level.
Twelve indentations were randomly made in cortical bone with
a NHT-TTX system (Anton Paar, Les Ulis, France) at distance
from osteocyte lacuna and microcracks. Loading/unloading was
performed at a rate of 40 mN/min up to a depth of 900 nm. At
maximum load, a holding period of 15 s was applied to avoid
creeping of the bone material. The following material properties
at the tissue-level, maximum load (Force max), indentation
modulus (EIT), hardness (HIT) and dissipated energy (Wplast),
were determined according to Oliver and Pharr (36).
After nanoindentation, cross-sections were stained with
toluidine blue and cortical thickness and cross-sectional moment
of inertia alongside the antero-posterior axis were computerized.
Fourier-Transform Infrared Imaging (FTIRI)
Cross-sectional sections (4µm) of the midshaft femur were
sandwiched between barium fluoride optical windows. Cross-
sections were divided into four quadrants (anterior, posterior,
lateral and medial) and all subsequent infrared acquisitions and
analyses have been performed at the posterior quadrant. FTIRI
was performed with a vertex 70 spectrometer (Bruker, Ettlingen,
Germany) interfaced with a Hyperion 3,000 microscope and a
focal plane array detector (64 × 64 pixels) covering a field of
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view of 180 × 180µm. Nine field-of-view were stitched together
to allow sufficient bone to be analyzed. Sections were scanned
with a spectral resolution of 8 cm−1 (spectral region 900–2,000
cm−1). Each spectrum was corrected for Mie scattering with
the RMieS-EMSC_v5 algorithm (kind gift of Prof Peter Gardner,
University of Manchester, UK) prior to be subjected to pMMA
substraction. Evaluation of spectral images was done with a
lab-made routine script in Matlab R2016b (The Mathworks,
Natick, MA) as previously described (37). FTIR bone parameters
(38) calculated were: (1) mineral/matrix ratio (area of v1, v3
phosphate/area amide1); (2) acid phosphate content (intensity
ratio 1,127cm−1/1,096 cm−1) (39); (3) mineral crystallinity
(intensity ratio 1,030 cm−1/1,020 cm−1), reflecting crystal size
and perfection; and (4) collagen maturity (intensity ratio 1,660
cm−1/1,690 cm−1). The carbonate/phosphate ratio (intensity v3
carbonate located at ∼1,415 cm−1/1,030 cm−1) was computed
after substracting the organic matrix spectrum (40). For each
of the compositional parameters, the mean and full width at
half maximum of the pixel distribution (excluding the zero
background values) were computed and represented as mean
and heterogeneity.
Statistical Analysis
Mechanical, structural, histomorphometrical and compositional
data were analyzed using Prism 6.0 (GraphPad Software Inc,
La Jolla, CA). Due to the adaptive nature of bone and an
observed higher body mass in HFD + saline animals, in
vivo data were adjusted for body-size (body mass × femur
length) using a linear regression method as reported in detail
elsewhere (41). An analysis of variance (ANOVA) was employed
to test for significance in any of the studied parameters. The
normality in data distribution was tested with the Brown-
Forsythe test. The association between mechanical properties,
plasma glucose level, cortical bone microarchitecture and bone
compositional parameters were investigated by stepwise multiple
regression analysis with a probability estimate of 0.15 and
a tolerance of 0.1 using Systat 13 (Systat Software Inc., San
Jose, CA). Multiple linear regression models were constructed,
making the dependent variable a function of non-fasting plasma
glucose levels, collagen maturity, phosphate/amide ratio, mineral
crystallinity, carbonate/phosphate ratio and acid phosphate
content. Differences at p equal or less than 0.05 were considered
significant.
RESULTS
HFD Animals Exhibit a Higher Body Mass
but Lower Bone Mineral Densities
As presented in Table 1, body and fat masses, non-fasting glucose
and glucose tolerance levels were significantly increased in the
HFD + saline group as compared with lean + saline animals.
Administration of exenatide in HFD mice had no effect on food
intake as well as body and fat masses but significantly reduced
non-fasting glucose levels by 59% (p < 0.001) and augmented
non-fasting insulin levels by 84% (p = 0.003). In addition,
exenatide significantly improved glucose tolerance (p= 0.05) and
peripheral insulin sensitivity (p= 0.05) when compared to saline
treated HFDmice (Table 1). Bone mineral density assessed either
for the whole body or at lumbar or femur sites revealed significant
lower values in HFD + saline mice as compared with lean +
saline animals (Table 1). On the other hand, administration of
exenatide in HFD mice did not ameliorate bone mineral density
at any site.
Administration of Exenatide Ameliorated
Bone Mechanical Properties at the Organ
Level
Next, we thought it prudent to ascertain biomechanical resistance
of bone tissue at both the organ and tissue levels. As represented
in Table 2, HFD+ saline animals presented with a compromised
bone mechanical properties at the organ level as suggested
by significant lower values for all mechanical parameters
investigated. Administration of exenatide ameliorated bone
mechanical properties at the organ level in HFDmice as revealed
by significant augmentations in all mechanical parameters.
Administration of Exenatide Improved Also
Mechanical Properties at the Tissue Level
Bone mechanical properties have been investigated at the tissue
level by two methods. The first one used equations from
engineering beam theory has a first estimate (Table 2). Ultimate
stress, yield stress, ultimate strain, post-yield strain and elastic
modulus were all reduced in HFD + saline animals as compared
with lean + saline mice. Administration of exenatide, only
improved significantly ultimate strain and post-yield strain.
Bone mechanical properties have also been investigated by
nanoindentation in femur cortical bone. As compared with lean
+ saline, maximum force, indentation modulus, indentation
hardness and work of indentation were significantly reduced in
HFD + saline animals. Administration of exenatide in these
animals, only ameliorated the hardness of the bone matrix by
25% (p < 0.001).
Administration of Exenatide Ameliorated
the Compromised Trabecular Bone
Microarchitecture Observed in HFD Mice
As bone mechanical properties at the organ level depends on
bone structural and bone compositional properties, we next
investigated trabecular and cortical bone microarchitectures.
Figure 2A represents 3D models of coronal sections of tibias.
HFD + saline animals seems to exhibit lower trabecular
bone in the proximal tibia metaphysis, while administration of
exenatide increases this parameter. Indeed, careful investigation
of trabecular microarchitecture (Figure 2B) highlighted that, as
compared with the lean + saline group, HFD + saline animals
presented with lower trabecular bone volume. Alterations of
the trabecular network were also evident and represented by
reductions in trabecular number and trabecular thickness, and
augmentation in trabecular spacing. Administration of exenatide
significantly augmented trabecular bone volume and improved
the connectivity of the trabecular network by significantly
increasing both trabecular number and thickness. Although a
tendency to lower values for Tb.Sp were observed in HFD +
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TABLE 1 | Effects of HFD-induced diabetes and treatment with exenatide on metabolic and compositional parameters.
Lean + saline HFD + saline HFD + Ex
Daily food intake (g) 4.2 ± 0.3 3.9 ± 0.3 3.6 ± 0.2
Body mass (g) 43 ± 2*** 58 ± 3 54 ± 1$$
Fat mass (%) 26 ± 2* 34 ± 2 34 ± 1$
Non-fasting glucose (mM) 4.9 ± 0.2*** 22.5 ± 2.7 9.3 ± 2.2***
Non-fasting insulin (mM) 1.8 ± 0.3 2.5 ± 0.4 4.6 ± 0.5**,$$$
Glucose tolerance (AUC0−60min) (mM.min) 719 ± 73** 1,043 ± 102 810 ± 25*
Insulin sensitivity (AAC0−60min ) (%change plasma glucose. min) 2,192 ± 130*** 1,166 ± 127 1,829 ± 155*
Whole body bone mineral density (mg/cm²) 72 ± 1*** 53 ± 1 59 ± 1$
Lumbar bone mineral density (mg/cm²) 72 ± 3*** 54 ± 2 60 ± 2*
Femur bone mineral density (mg/cm²) 115 ± 3** 91 ± 3 102 ± 4*
For glucose tolerance tests, blood glucose concentrations were measured before and 15, 30, and 60min after i.p injection of glucose (18 mmol/kg), with 0–60min AUC values noted in
Table. For peripheral insulin sensitivity, blood glucose concentrations were measured before and 15 and 60min after i.p injection of insulin (10 U/kg), with 0–60min AAC values noted
in Table. Glucose tolerance tests were conducted in mice fasted for 18 h whereas insulin sensitivity tests were conducted in non-fasted mice.
*p ≤ 0.05, **p < 0.01, ***p < 0.001 vs. HFD + saline. $p ≤ 0.05, $$p < 0.01, $$$p < 0.001 vs. Lean + saline. Values are means ± SEM for 8 mice.
TABLE 2 | Effects of HFD-induced diabetes and treatment with exenatide on bone mechanical response at the organ and tissue levels.
Lean + saline HFD + saline HFD + Ex
ORGAN LEVEL
Ultimate load (N) 34.7 ± 1.5*** 25.2 ±1.3 30.8 ± 1.3**
Yield load (N) 26.1 ± 1.4*** 18.7 ±1.0 22.8 ± 1.2*
Ultimate displacement (mm) 0.48 ± 0.04*** 0.24 ±0.01 0.33 ± 0.02*,$$$
Post-yield displacement (mm) 0.30 ± 0.04*** 0.10 ±0.01 0.18 ± 0.02*,$$
Stiffness (N/mm) 177 ± 10*** 121 ±7 152 ± 8*,$
Work-to-failure (N.mm) 9.5 ± 1.0*** 4.2 ±0.5 7.0 ± 0.5**,$
TISSUE LEVEL (3-POINT BENDING)
Ultimate stress (MPa) 237 ± 12*** 164 ±10 189 ± 8$$
Yield stress (MPa) 177 ± 9*** 122 ±8 139 ± 8$
Ultimate strain 0.050 ± 0.004*** 0.025 ±0.002 0.035 ± 0.002*,$$
Post-yield strain 0.031 ± 0.004*** 0.011 ±0.001 0.020 ± 0.002*,$
Elastic modulus (GPa) 11.8 ± 0.8*** 7.6 ±0.5 8.8 ± 0.5$$
TISSUE LEVEL (NANOINDENTATION)
Maximum force (mN) 17.7 ± 0.6*** 11.4 ±0.8 12.8 ± 0.6$$$
Indentation modulus (GPa) 18.9 ± 0.4*** 12.9 ±0.5 13.8 ± 0.5$$$
Indentation hardness (MPa) 980 ± 22*** 605 ±24 759 ± 17***,$$$
Work of indentation (pJ) 4,285 ± 157*** 2,837 ±141 3,000 ± 138$$$
*p < 0.05, **p < 0.01, ***p < 0.001 vs. HFD + saline. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. Lean + saline. Values are means ± SEM for 8 mice.
Ex mice, this parameter did not reach statistical significance
(p= 0.084).
Furthermore, cortical bone microarchitecture was also
modified in HFD + saline group compared with lean + saline
animals and represented by lower values for cortical thickness
and cross-sectional moment of inertia about the anteroposterior
axis. Administration of exenatide in HFD animals did not result
in significant improvements in any of these cortical parameters.
At the matrix and cellular levels, osteoid thickness was
not different between the three groups of animals suggesting
that initiation of bone mineralization was not altered. Osteoid
surfaces were significantly lowered in HFD + saline mice
as compared with lean + saline controls. Administration of
exenatide significantly augmented osteoid surfaces suggesting
new bone formation. This is even corroborated by the number
of osteoblasts that was reduced in HFD + saline animals and
augmented after administration of exenatide. No modifications
in the number of osteoclasts was observed between the three
groups of animals. However, bone marrow adiposity parameters
were not significantly different between lean + saline and
HFD + saline animals (Figure 2C). On the other hand, the
administration of exenatide in HFD animals led to significant
augmentations of adiposity volume and number of adipocytes in
the bonemarrow. The number of osteoclasts was not significantly
different between the three groups of animals. On the other hand,
the number of osteoblasts was significantly reduced in HFD +
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FIGURE 2 | Effects of HFD-induced diabetes and treatment with exenatide on trabecular and cortical bone microarchitectures. (A) Three-dimensional models of tibias
were reconstructed and highlight differences in trabecular bone network. (B) Trabecular microarchitecture parameters determined at the proximal tibia and cortical
microarchitecture parameters measured at the midshaft femur. BV/TV: trabecular bone volume, Tb.N: trabecular number, Tb.Th: trabecular thickness, Tb.Sp:
trabecular spacing, Ct.Th: cortical thickness and Iap: cross-sectional moment of inertia about the anteroposterior axis. *p < 0.05, **p < 0.01, ***p < 0.001 vs. HFD +
saline. $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. Lean + saline. Values are means ± SEM for 8 mice. (C), Histomorphometrical parameters measured at the proximal
tibia. O.Th, osteoid thickness; OS/BS, osteoid surface; N.Ob/B.Pm, number of osteoblasts; N.Oc/B.Pm, number of osteoclasts; N.Ad/Ma.Ar, adipocyte number;
Ad.Ar/Ma.Ar, bone marrow adiposity volume; Ad.Ar, adipocyte area. *p < 0.05, **p < 0.01, ***p < 0.001 vs. HFD + saline. $$p < 0.01, $$$p < 0.001 vs. Lean +
saline.
saline animals (−50%, p = 0.003) as compared with lean animal.
The administration of exenatide led to a significant augmentation
in this parameter.
Administration of Exenatide Modified Bone
Compositional Parameters in HFD Mice
Next, as bone composition has been suspected to be altered
in T2DM, we investigated compositional parameters over the
full cortical width by infrared imaging. Figure 3 represents
infrared images over the cortical width of the lean + saline,
HFD + saline, and HFD + Ex groups. Some differences in
the pixel intensity distribution in the bone matrix were obvious
especially for collagen maturity, carbonate/phosphate ratio and
acid phosphate content. Indeed, as compared with lean +
saline animals, HFD + saline mice exhibited a significant
23% reduction (p < 0.001) in the mean collagen maturity
whilst heterogeneity was not significantly different. None of
the other compositional parameters, investigating mostly the
mineral composition and crystallinity, were different between
the two groups of animals. Administration of exenatide to HFD
mice led to a significant augmentation in the mean collagen
maturity. Significant lower values for the mean crystallinity as
well as mean and heterogeneity of carbonate/phosphate ratio
were also observed with exenatide treatment. In contrast, the
mean and heterogeneity of acid phosphate content presented
with significant higher mean values.
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FIGURE 3 | Effects of HFD-induced diabetes and treatment with exenatide on bone compositional parameters. Bone composition parameters were assessed by
Fourier transform infrared imaging (FTIRI) at the posterior quadrant of the femur. Some FTIRI images, representing the overall stitching of nine consecutive
field-of-views, are presented. The pseudo-color represents the degree of each parameter overall the full width of the cortical bone. The mean and width at half
maximum, representing the mean and heterogeneity, respectively, of each parameter was also investigated and represented below FTIRI images. Values are means ±
SEM for 8 mice. *p < 0.05, **p < 0.01, ***p < 0.001 vs. HFD + saline. $p < 0.05, $$$p < 0.001 vs. Lean + saline.
Contribution of Changes in Plasma
Glucose Levels, Microarchitectural and
Compositional Parameters to Mechanical
Property of Cortical Bone
In order to decipher the possible association between mechanical
outcome and plasma glucose levels, microarchitectural and
compositional parameters, we constructed several multiple
regression models summarized in Table 3. Ultimate load was
inversely associated with plasma glucose when saline-treated
animals only were considered. However, in HFD animals,
ultimate load depended greatly of carbonate/phosphate ratio
and weakly to plasma glucose. Ultimate displacement was only
associated with collagen maturity in saline-treated animals. In
HFD animals, this mechanical parameter was greatly associated
with mineral crystallinity, mildly with acid phosphate content
and collagen maturity, and weakly with plasma glucose. In
saline-treated animals, stiffness was associated only with cortical
thickness. In HFD animals, stiffness was associated with acid
phosphate content and carbonate/phosphate ratio. However,
it is worth noting that although these two regression models
were statistically significant, the adjusted R2 was relatively poor
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TABLE 3 | Multiple regression analyses of the relations between mechanical properties, plasma glucose level, cortical bone microarchitecture, and bone compositional
parameters.
Dependent variable Groups Model adjusted R² Model p-value Parameter β Parameter p-value
Ultimate load Saline-treated 0.650 <0.001 Plasma glucose −0.556 <0.001
HFD 0.507 0.017 Plasma glucose −0.697 0.007
Carbonate/phosphate ratio −27.737 0.039
Ultimate displ. Saline-treated 0.903 <0.001 Collagen maturity 0.630 0.001
HFD 0.824 0.002 Plasma glucose −0.011 0.010
Collagen maturity 0.726 0.013
Mineral crystallinity −6.430 0.019
Acid phosphate content 0.855 0.012
Stiffness Saline-treated 0.336 0.011 Ct.Th 0.411 0.011
HFD 0.481 0.021 Acid phosphate content 368.2 0.009
Carbonate/phosphate ratio 148.85 0.010
PYD Saline-treated 0.611 0.002 Collagen maturity 0.212 0.002
HFD 0.433 0.012 Collagen maturity 0.499 0.012
Work-to-fracture Saline-treated 0.761 <0.001 Collagen maturity 9.073 <0.001
HFD 0.729 0.008 Plasma glucose −0.357 0.022
Collagen maturity 22.5 0.033
Mineral crystallinity −166.2 0.035
Acid phosphate content 21.403 0.048
(0.336–0.481). In saline-treated and HFD-treated animals, post-
yield displacement was linked to collagen maturity. Work to
fracture was only associated with collagen maturity in saline-
treated animals with a relatively good adjusted R2 of 0.761.
In HFD animals, work-to-fracture was associated strongly with
mineral crystallinity, mildly with acid phosphate content and
collagen maturity and weakly with plasma glucose.
DISCUSSION
Although patterns of T2DM differ by ethnic group and lifestyle,
refined carbohydrates and saturated fat, which contribute to fat
deposition in peripheral tissues and weight gain, are recognized
important risk factors for development of T2DM. Indeed,
overweight and obesity have been estimated to account for
about 65–80% of new cases of T2DM (42). Patients with type
2 diabetes mellitus have an increased risk of bone fractures
(1, 2). However, the exact underlying mechanism linking T2DM
to higher fracture risk is poorly characterized. In the present
study, we investigated changes in bone mechanical properties
plus bone microarchitectural and compositional parameters
in NIH swiss mice fed a high fat diet. In opposition to
C57BL/6 mice, the NIH swiss model develop a frank fasting
hyperglycemia (>14 mmol/L) over 112 days of high fat feeding
and represents a validated model of obesity-induced T2DM
(43). The potential effects of sustained treatment with exenatide,
a GLP-1 receptor agonist drug already approved for the
treatment of T2DM, in restoring bone mechanical properties was
also investigated.
We found that HFD led to reduction of bone mineral
density at all studied sites, and that this was associated with
compromised bone mechanical properties not only at the organ
but also at the tissue level, suggesting possible alterations of
structural and compositional properties. Indeed, alterations of
trabecular and cortical bone microarchitectures, bone cell count
and compositional properties were undoubtedly evidenced.
Administration of exenatide in this diabetic murine model led
to significant improvement in all mechanical parameters at
the organ level as well as amelioration in trabecular (BV/TV,
Tb.N, Tb.Th) microarchitectures. Similar observations have
been observed by others previously in several animal models
of type 2 diabetes mellitus (25–27, 44). However, although a
controversy exist on the presence of a functional GLP-1 receptor
in bone cells, it is challenging to ascertain whether amelioration
in trabecular microarchitecture, mechanical competency and
changes in bone composition are due to direct effects on bone
cells or indirect effects. Previously, in the db/db mouse model, we
found that exenatide was capable of restoring impaired hindlimb
blood flow that potentially could participate to better trabecular
microarchitecture and bone formation (27).
Poor glycemic control is also an important factor suspected
to act in the etiology of bone fracture in diabetes. Marked
hyperglycemia was observed in the present study and
administration of exenatide, as expected, reduced plasma
glucose level. Multiple regression analyses revealed that although
reduction in plasma glucose level participated in improvement
in bone mechanical properties, its contribution was relatively
modest and it did not appear as the main contributing factors.
However, these results are to be weighted by the fact that
reducing hyperglycemia might affect bone cell physiologies
by reducing chronic inflammation and accumulation of
advanced glycation end-products and hence might influence
mineral deposition but also collagen cross-linking. As such, the
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contribution of lower plasma glucose levels to bone mechanical
properties might have been higher than detected by multiple
regression analyses.
The originality of our study resides in the investigation of
compositional parameters as to the best of our knowledge;
this has not yet been assessed previously and might provide
an explanation for the decline in bone mechanical properties
at the organ and tissue levels. The multiple regression
analyses highlighted the important role of bone compositional
parameters in bone mechanical properties as collagen maturity
was a strong contributor to bone mechanical properties in
saline treated animals (β between 0.212 and 9.73). In HFD
animals, here again, collagen maturity, mineral crystallinity,
carbonate/phosphate ratio and acid phosphate content were
strong predictors of bone mechanical properties. Apart for
bone stiffness, the high values of model adjusted R² suggested
a good agreement between experimental data and regression
model. Furthermore, the energy required to fracture bone
in three-point bending, and estimated as work-to fracture,
was clearly dependent on compositional parameters rather
than plasma glucose levels. Collagen maturity is a parameter
reflecting the ratio of enzymatic mature (pyridinoline) over
immature (dehydrodihydroxylysinonorleucine) collagen cross-
links. However, collagen cross-linking is the result of enzymatic
(lysine hydroxylase and lysine oxidase) and non-enzymatic,
AGE driven, intermolecular bridging of collagen fibrils. The
intermolecular cross-linking of bone collagen is a chemical
feature that is intimately related to the way matrix collagen
molecules are arranged in fibrils and provides fibrillary matrices
with important mechanical properties such as tensile mechanical
properties and viscoelasticity (45, 46). Non-enzymatic collagen
cross-linking is represented by the accumulation of AGEs in
the organic matrix and measurable by FTIRI (47). However,
the required EDTA treatment led to very fragile bone sections
and in the present study, more than 70% of our bone sections
were not usable after EDTA treatment. This is unfortunate, as
a reduction in AGE content could also have participated in
ameliorating bone mechanical properties by directly affecting
local mechanical response, but also by influencing the fate of
bone cells.
Interestingly, exenatide administration resulted in reductions
in mineral crystallinity, mean carbonate/phosphate ratio and its
distribution heterogeneity and augmentation of acid phosphate
content and heterogeneity. These mineral properties were
unaffected by high fat diet and these observations suggest that
the bone action of exenatide is beyond the simple reduction
in plasma glucose levels and elevation in insulin level and
sensitivity. However, it is worth noting that changes in mineral
composition and crystallinity was not previously observed in the
db/dbmicemodel (27). Although in our study the administration
of exenatide was for a longer period of time (∼7.5 weeks vs. 4
weeks), this discrepancy might highlight differences in response
to exenatide based on the etiology of type 2 diabetes (monogenic
vs. lifestyle).
A limitation to this study is represented by the lack of
administration of calcein or other fluorochromes before sacrifice.
Indeed, withouth thesemarkers of mineralization, it is impossible
to assess dynamic histomorphometry and extent of bone
formation. Also, it was not possible to adjust bone composition
for tissue age as well as determined whether the observed
improvement with exenatide was due to a bone matrix of better
quality laid down during exenatide treatment or to amelioration
of bone matrix made before exenatide administration.
Recent interest in marrow adipose tissue has revealed an
unexpected role of marrow adipocyte in bone physiology.
Interestingly and in contrast with previous published studies of
high fat diet in the C57BL/6 congenic mouse strain (48, 49),
marrow adipose volume and the number of marrow adipocytes
were unchanged in HFD mice treated with saline. Others have
clearly highlighted previously that mouse strain, gender and
age of initiation of high fat diet likely play important role in
determining the effect of HFD on bone marrow composition
and skeletal phenotype (50, 51). The reason for the lack of
increase in marrow adiposity in HFD + saline mice in the
present study is unknown. However, it is worth noting that in
humans, T2DM is not associated with an increase in marrow
adipose tissue but rather marrow adipose tissue was positively
correlated with HbA1c level (52). However, administration of
exenatide in high fat fed animals resulted in changes in marrow
adipose tissue. Marrow adipocytes and osteoblasts derived both
from the same common non-hematopoietic non-endothelial
CD45− CD31− Sca1+ CD24+ mesenchymal stem cells (53).
Previous studies have highlighted the complex action of GLP-
1 and its analogs on bone marrow mesenchymal stem cells
with apparent higher proliferation of uncommitted progenitors
resulting in higher osteoblast and marrow adipocyte numbers
(54). Our results support these observations as the number
of osteoblasts and marrow adipocytes were both elevated in
response to exenatide. However, adipocyte-committed precursor
cells are suspected to restrain osteoblast differentiation and
bone formation. Adipogenic precursor cells express high level
of the dipeptidyl peptidase-4 and their negative action on bone
formation is alleviated by administration of a dpp-4 inhibitor
(53). However, as exenatide is designed to be dpp-4 resistant,
it is possible that in our study, this drug was unaffected by
dpp-4 overexpression.
In conclusion, the present study provides new insight into the
mode of action of exenatide on bone in diabetes. Indeed, not only
did this agent ameliorated cortical bone microarchitecture but
it also led to critical changes in bone composition that resulted
in improvement of overall bone mechanical properties. Further
studies are required to ascertain whether such effects occur in
humans, but the results of this study are highly encouraging
to the goal of improving bone mechanical properties in
type-2 diabetes.
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